Veraxa Biotech AG

Veraxa Biotech AG is a clinical-stage biotechnology company focused on developing next-generation antibody-based cancer therapies. The company, headquartered in Zurich, Switzerland, with R&D operations in Heidelberg, Germany, originated from scientific discoveries made at the European Molecular Biology Laboratory (EMBL). Veraxa Biotech AG's proprietary Bi-Targeted Antibody Cytotoxicity (BiTAC) platform is central to its strategy. This platform enables the development of novel antibody-based drug platforms, including bispecific antibody-drug conjugates (BiTAC ADCs and bsADCs) and bispecific immune cell engagers, such as T-cell engagers. The BiTAC platform utilizes a dual-marker targeting approach, enhanced with AI-enabled discovery, to precisely target cancer cells while aiming to leave healthy cells intact. This approach seeks to improve the safety and efficacy profiles of solid tumor treatments and expand their therapeutic window compared to existing standards of care. The company is advancing a pipeline of discovery and development programs, primarily focused on solid tumors, with an active Phase 1 leukemia program. Its lead clinical asset is VX-A901, an Fc-enhanced antibody targeting FLT3. Veraxa Biotech AG became a publicly traded oncology biotechnology company on Nasdaq, trading under the ticker symbol VRXA, following a business combination with Voyager Acquisition Corp. Sources: [1] https://www.listingtrack.io/company?name=Veraxa%20Biotech%20AG&symbol=VRXA [2] https://www.thepharmaletter.com/veraxa-biotech [3] https://www.globenewswire.com/news-release/2026/06/10/3310101/0/en/veraxa-biotech-to-debut-as-a-publicly-traded-company-pioneering-next-generation-cancer-therapies-on-june-11-2026.html [4] https://marketchameleon.com/Overview/VRXA/About/ [5] https://markets.businessinsider.com/news/currencies/veraxa-biotech-nasdaq-vrxa-completes-business-combination-begins-trading-on-nasdaq-1036243518 [6] https://www.veraxa.com/about-us [7] https://www.biospace.com/press-releases/veraxa-biotech-to-debut-as-a-publicly-traded-company-pioneering-next-generation-cancer-therapies-on-june-11-2026